The UK company boasts a team with over 200 years of combined experience in the pharma sector, focusing on rare diseases where there is a lack of hospital analytical services and no approved drugs. They have identified a significant market gap. Their core markets include the EU, US, and ME, helping hospital providers enhance understanding of rare disease patient populations . The company is actively developing a portfolio of commercial and clinical-stage therapeutic assets through acquisition, licensing, and collaborations. This strategic approach allows for rapid integration of innovative therapies, supporting expedited clinical trials and regulatory approvals.

• Leadership team with extensive experience and international connections in the pharma industry.
• Application of expertise specifically in the rare disease sector.
• Utilization of analytical tools to deliver superior insights into patient populations, facilitating drug portfolio development for effective treatment

The company seeks partners who are either the owners or innovators behind orphan drugs that have been unable to commercialize, considering a range of development stages. Partners may pursue options for acquisition, licensing, and collaborations. Additionally, the company is interested in collaborating with partners who have laboratory facilities for developing drug strains, facilitating further advancements in therapeutic asset development .